查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468123

2024-2032 年高血磷症藥物市場報告（依產品、劑型、配銷通路及地區）

Hyperphosphatemia Drugs Market Report by Product, Dosage Form, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球高血磷症藥物市場規模達41億美元。末期腎病（ESKD）盛行率的上升、易患慢性疾病的老年人口的大幅增加以及健康意識的提高導致早期疾病診斷的趨勢不斷上升，這些都是推動市場發展的一些關鍵因素。

高磷酸鹽血症的特徵是由於磷酸鹽攝取增加、磷酸鹽遷移出細胞、磷酸鹽排泄減少而導致血液中磷酸鹽水平升高。高磷血症常見於患有慢性腎臟疾病、糖尿病酮酸中毒、未控制的糖尿病和副甲狀腺素水平低的人。治療高血磷症的藥物往往含有磷酸鹽結合劑，有助於控制血液中高水平的磷酸鹽。此外，高磷血症藥物可有效減少胃腸道對磷的吸收。它們將陰離子磷酸鹽與活性陽離子（例如碳酸鹽、乙酸鹽、羥基氧化物或檸檬酸鹽）交換，形成不可吸收和排泄的化合物。

高血磷症藥物市場趨勢：

全球各種慢性疾病，特別是末期腎病（ESKD）盛行率的上升是推動市場成長的重要因素。這可以歸因於易患這些疾病的老年人口數量大幅增加。與此一致的是，由於新藥批准而推出的產品數量不斷增加，對市場產生了積極影響。此外，在眾多臨床試驗中引入強大的管道藥物正在為市場創造利潤豐厚的成長機會。然而，高磷血症藥物日益嚴重的副作用、多個國家藥品管理機構監管的日益嚴格以及高昂的生產成本正在限制市場的成長。相反，藥品生產過程中廣泛的研發（R＆D）活動正在為市場創造積極的前景。除此之外，主要參與者為擴大其地理影響力而大幅增加的合作、夥伴關係和策略併購（M&A）也為市場提供了動力。人們對傳統磷酸鹽結合劑藥物的偏好轉變為採用非磷酸鹽結合劑藥物，進一步推動了市場的發展。此外，不斷增加的醫療支出以及醫療基礎設施的持續技術進步正在推動市場。推動市場發展的其他因素包括快速城市化、產品高階化、早期疾病診斷的上升趨勢、生物技術產業的大幅成長以及可支配收入水準的提高。

本報告回答的關鍵問題：

  • 迄今為止，全球高血磷症藥物市場表現如何，未來幾年將如何表現？
  • 全球高磷血症藥物市場的促進因素、限制因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的高血磷症藥物市場？
  • 基於產品的市場區隔是什麼？
  • 根據劑型，市場的詳細情形如何？
  • 基於配銷通路的市場區隔是什麼？
  • 全球高血磷症藥物市場競爭格局如何？
  • 全球高血磷症藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球高血磷症藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品

  • 司維拉姆
    • 市場走向
    • 市場預測
  • 鈣基磷酸鹽結合劑
    • 市場走向
    • 市場預測
  • 鐵基磷酸鹽結合劑
    • 市場走向
    • 市場預測
  • 碳酸鑭
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按劑型

  • 平板電腦
    • 市場走向
    • 市場預測
  • 糖漿
    • 市場走向
    • 市場預測
  • 膠囊
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Ardelyx Inc.
    • Fresenius Medical Care AG & Co. KGaA
    • Lupin Pharmaceuticals Inc (Lupin Limited)
    • Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
    • Vifor Pharma Management Ltd. (CSL Limited)
Product Code: SR112024A6746

The global hyperphosphatemia drugs market size reached US$ 4.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.8 Billion by 2032, exhibiting a growth rate (CAGR) of 7.07% during 2024-2032. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.

Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.

Hyperphosphatemia Drugs Market Trends:

The rising prevalence of various chronic diseases, particularly end stage kidney disease (ESKD), across the globe is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the geriatric population that is susceptible to developing these ailments. In line with this, the increasing number of product launches due to the approval of novel drugs are positively impacting the market. Also, the introduction of strong pipeline drugs in numerous clinical trials is creating lucrative growth opportunities in the market. However, the growing side effects of hyperphosphatemia drugs, the rising stringency in regulations by the drug-governing bodies in several countries, and high production costs are restraining the market growth. On the contrary, extensive research and development (R&D) activities in drug manufacturing procedures are creating a positive outlook for the market. Apart from this, a significant increase in collaborations, partnerships and strategic merger and acquisition (M&As) by the key players to extend their geographical presence is also providing an impetus to the market. The market is further fueled by the shifting preference toward the adoption of non-phosphate binder drugs from the conventional phosphate binder drugs. Moreover, the increasing medical expenditure, along with continual technological improvements in the healthcare infrastructure facilities, are propelling the market. Some of the other factors contributing to the market include rapid urbanization, product premiumization, the rising trend of early disease diagnosis, considerable growth in the biotechnology industry and inflating disposable income levels.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global hyperphosphatemia drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, dosage form, and distribution channel.

Product Insights:

Sevelamer

Calcium Based Phosphate Binders

Iron Based Phosphate Binders

Lanthanum Carbonate

Others

The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the product. This includes sevelamer, calcium based phosphate binders, iron based phosphate binders, lanthanum carbonate, and others. According to the report, sevelamer represented the largest segment.

Dosage Form Insights:

Tablets

Syrups

Capsules

The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the dosage form. This includes tablets, syrups, and capsules. According to the report, tablets represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the hyperphosphatemia drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hyperphosphatemia drugs. Some of the factors driving the North America hyperphosphatemia drugs market include the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global hyperphosphatemia drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hyperphosphatemia drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive hyperphosphatemia drugs markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the dosage form?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global hyperphosphatemia drugs market?
  • Who are the key players/companies in the global hyperphosphatemia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hyperphosphatemia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Sevelamer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Calcium Based Phosphate Binders
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Iron Based Phosphate Binders
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Lanthanum Carbonate
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Dosage Form

  • 7.1 Tablets
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Syrups
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Capsules
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ardelyx Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Fresenius Medical Care AG & Co. KGaA
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Pharmaceuticals Inc (Lupin Limited)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Vifor Pharma Management Ltd. (CSL Limited)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Hyperphosphatemia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Hyperphosphatemia Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hyperphosphatemia Drugs Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Hyperphosphatemia Drugs Market: Breakup by Dosage Form (in %), 2023
  • Figure 6: Global: Hyperphosphatemia Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Hyperphosphatemia Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Hyperphosphatemia Drugs (Sevelamer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Hyperphosphatemia Drugs (Sevelamer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Hyperphosphatemia Drugs (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Hyperphosphatemia Drugs (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Hyperphosphatemia Drugs (Tablets) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Hyperphosphatemia Drugs (Tablets) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Hyperphosphatemia Drugs (Syrups) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Hyperphosphatemia Drugs (Syrups) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Hyperphosphatemia Drugs (Capsules) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Hyperphosphatemia Drugs (Capsules) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Hyperphosphatemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Hyperphosphatemia Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Hyperphosphatemia Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 80: Global: Hyperphosphatemia Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Hyperphosphatemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hyperphosphatemia Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Dosage Form (in Million US$), 2024-2032
  • Table 4: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Hyperphosphatemia Drugs Market: Competitive Structure
  • Table 7: Global: Hyperphosphatemia Drugs Market: Key Players